Clinical Trial

A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy

Name: A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy — clinical trial record (NCT07642050)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The purpose of this study is to determine if BHV-1400 is effective and safe in the treatment of IgA Nephropathy. Participants will be randomized in a 2:1 ratio to receive either BHV-1400 or placebo.

Trial Details

NCT Number	NCT07642050
Lead Sponsor	Biohaven Therapeutics Ltd.
Conditions	IgA Nephropathy
Enrollment	420 participants
Start Date	2026-06
Primary Completion	2028-09 (estimated)
Study Completion	2029-10 (estimated)
Updated on ClinicalTrials.gov	2026-06-11